Functionally Improved Mesenchymal Stem Cells to Better Treat Myocardial Infarction

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Stem Cell Therapy

Background:

• Myocardial infarction (MI) remains a primary global cause of mortality.
• Mesenchymal stem cell (MSC) transplantation is a promising therapeutic strategy for MI, with progress in preclinical and clinical settings.
• Current limitations in MSC therapy for MI include poor cell survival, retention, homing, and differentiation.

Purpose of the Study:

• To review strategies for enhancing Mesenchymal stem cell (MSC) therapy for myocardial infarction (MI).
• To discuss modifications of both MSCs and the host cardiac environment to improve therapeutic outcomes.
• To provide an overview of current advancements and challenges in MSC-based MI treatment.

Main Methods:

• Review of existing literature on Mesenchymal stem cell (MSC) modifications for MI treatment.
• Analysis of strategies for optimizing the transplantation microenvironment in the myocardium.
• Synthesis of data from preclinical studies and clinical trials of MSC therapy for MI.

Main Results:

• Various approaches exist to improve MSC survival, retention, homing, and differentiation.
• Preconditioning, genetic modification, cotransplantation with bioactive factors, and tissue engineering are key MSC modification strategies.
• Optimizing the host myocardial microenvironment is crucial for enhancing therapeutic efficacy.

Conclusions:

• Modifying Mesenchymal stem cells (MSCs) and the host myocardium are essential for improving MSC-based therapy for myocardial infarction (MI).
• Addressing current limitations through innovative strategies can unlock the full potential of MSCs in treating heart disease.
• Further research and clinical translation are needed to fully establish MSC therapy as a standard treatment for MI.